---
figid: PMC8117216__fonc-11-670804-g002
figtitle: Repositioning of Antiparasitic Drugs for Tumor Treatment
organisms:
- Trypanosoma cruzi
- Plasmodium vivax
- Clonorchis sinensis
- Opisthorchis viverrini
- Schistosoma haematobium
- Streptomyces avermitilis
- Streptomyces bingchenggensis
- Streptomyces sp. FJS31-2
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Artemisia annua
organisms_ner:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC8117216
filename: fonc-11-670804-g002.jpg
figlink: /pmc/articles/PMC8117216/figure/f2/
number: F2
caption: Efficacy of benzimidazole antiparasitic drugs in cancer. Benzimidazoles can
  cause energy metabolism disorders and reduce cancer cell tolerance to hypoxic environments
  by (1) inhibiting the expression of HIF-1α and (2) inhibiting sugar intake through
  the GLUT/AMPK/P53 pathway. Apart from sugar metabolism, benzimidazoles also induce
  apoptosis by (3) inhibiting microtubule polymerization and (4) ER stress, and (5)
  promoting MAPK phosphorylation. By affecting numerous autophagy-related proteins
  (LC3, P62, and EVA1A) and downstream signals related to STAT3, benzimidazole can
  also cause (6) autophagic cancer cell death. (7) Benzimidazoles reduce the expression
  of PD-1 and (8) inhibit the accumulation of MDSC in the TME to stimulate antitumor
  immunity.
papertitle: Repositioning of Antiparasitic Drugs for Tumor Treatment.
reftext: Yan-Qi Li, et al. Front Oncol. 2021;11:670804.
year: '2021'
doi: 10.3389/fonc.2021.670804
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media S.A.
keywords: drug repositioning | antiparasitic drugs | macrolides | benzimidazoles |
  artemisinin | quinolines | autophagy | ferroptosis
automl_pathway: 0.9572733
figid_alias: PMC8117216__F2
figtype: Figure
redirect_from: /figures/PMC8117216__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8117216__fonc-11-670804-g002.html
  '@type': Dataset
  description: Efficacy of benzimidazole antiparasitic drugs in cancer. Benzimidazoles
    can cause energy metabolism disorders and reduce cancer cell tolerance to hypoxic
    environments by (1) inhibiting the expression of HIF-1α and (2) inhibiting sugar
    intake through the GLUT/AMPK/P53 pathway. Apart from sugar metabolism, benzimidazoles
    also induce apoptosis by (3) inhibiting microtubule polymerization and (4) ER
    stress, and (5) promoting MAPK phosphorylation. By affecting numerous autophagy-related
    proteins (LC3, P62, and EVA1A) and downstream signals related to STAT3, benzimidazole
    can also cause (6) autophagic cancer cell death. (7) Benzimidazoles reduce the
    expression of PD-1 and (8) inhibit the accumulation of MDSC in the TME to stimulate
    antitumor immunity.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Trp53
  - Slc1a3
  - Hif1a
  - Stradb
  - Eva1a
  - Tnf
  - Pdcd1
  - Tme
  - Map1lc3a
  - Gtf2h1
  - Nup62
  - Sqstm1
  - Khdrbs1
  - Dctn4
  - Tp53
  - Prkaa2
  - Gls
  - Anxa3
  - TP53
  - TP63
  - TP73
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - SLC2A1
  - HIF1A
  - STRADB
  - PAK1
  - PAK2
  - PAK3
  - PAK4
  - PAK5
  - PAK6
  - EVA1A
  - TNF
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - MAP1LC3A
  - GTF2H1
  - SQSTM1
  - KHDRBS1
  - NUP62
  - DCTN4
  - p53
  - betaTub60D
  - hth
  - SNF4Agamma
  - AMPKalpha
  - Eaat1
  - Glut1
  - Glut4EF
  - Glut3
  - sima
  - Pa
  - Pak
  - mbt
  - egr
  - Atg8a
  - ref(2)P
  - DCTN4-p62
  - Tfb1
  - Taf6
  - how
---
